Aim. The aim of the work was to study a possible influence of several genes polymorphism and of lipids on the effectiveness of one year dementia treatment with cholinesterase inhibitors.
Methods. The group consisted of 68 patients - 48 with Alzheimer's disease and 20 with mixed dementia. Apolipoprotein E alleles, two polymorphisms of LRP and two of interleukin 1ß genes were identified by DNA analysis. Lipid levels were determined in plasma using enzymatic methods.
Results. No one apolipoprotein E carrier was in the group of bad responders to treatment. A higher frequency of e4 allele carriers showed bad response to treatment as compared with e2 allele carriers. A higher frequency of carriers of the longer 92 allele of [TTTC]n LRP polymorphism and of carriers of T allele of the C766T LRP polymorphism and ofpersons with plasma LDL cholesterol level >135 mg/dl was observed in the group of bad responders comparing with their frequency in the good responders group. The more of those disadvantageous factors had an individual the significantly worse were his treatment results. It was concluded that APOE and LRP polymorphism as well as LDL cholesterol levels could have an influence on the effectiveness of treatment with acetylcholinesterase inhibitors in patients with dementia. The effect was stronger in Alzheimer's disease patients than in patients with mixed dementia.
Conclusions. Our results showed that APOE and LRP polymorphism as well as LDL cholesterol levels could modify the effectiveness of treating patients with dementia with acetylcholinesterase inhibitors.